Praxis surges after late-stage trial success for movement disorder therapy

Praxis Precision Medicines (PRAX) stock surges as its movement disorder therapy ulixacaltamide succeeds in two Phase 3 trials ...
Fierce Biotech

Praxis erases doubts with phase 3 wins in essential tremor, sending shares soaring

Praxis Precision Medicines’ commitment to forging ahead with ulixacaltamide in essential tremor (ET) has paid off. | The ...

Praxis Precision’s tremor-drug trial succeeds where others have failed. The stock is skyrocketing.

Shares of biopharmaceutical company Praxis Precision Medicines Inc. are soaring, boosted by the successful trial of a new ...

Praxis Precision Medicines, Inc. Announces Proposed Public Offering

TD Cowen, Piper Sandler, Guggenheim Securities and Truist Securities are acting as joint book-running managers for the offering. The offering is subject to market and other customary closing ...

Praxis Precision Medicines Announces Positive Topline Results from Two Pivotal Phase 3 Studies of Ulixacaltamide HCl in the Essential3 Program for Essential Tremor

Patients treated with ulixacaltamide in the parallel-group study (Study 1) showed a mean improvement from baseline in the Modified Activities of ...